Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.
8 reports, 2 independent
Updated Thu 00:00
Still developing
- Reports
- 8
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA issued Complete Response Letters to Unicycive Therapeutics, Inc.1 source
FDA cited manufacturing deficiencies at a vendor facility for Unicycive.1 source
FDA cited deficiencies at manufacturing vendor for Unicycive Therapeutics, Inc.1 source
FDA found manufacturing compliance issues at Unicycive Therapeutics, Inc.1 source
Keep exploring
The entities involved
-
Unicycive Therapeutics, Inc.
Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications
Nothing else this week.
- FDA
-
Nasdaq
American fully electronic stock exchange
Related events
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- Morgan Stanley was involved in market activity on the electronic stock exchange, with filings received regarding this activity.
- Direct Digital is voluntarily delisting from Nasdaq following SEC regulatory actions.
- Litigation regarding FDA approval process.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.